A Phase 1 Study of GRN163L (Imetelstat) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia That is in Second or Greater Relapse or That is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or is Refractory to Relapse Therapy

This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML) that has not responded to previous treatment (refractory) or that has come back after a period of improvement (recurrent). Imetelstat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as fludarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imetelstat in combination with fludarabine and cytarabine may work better in treating patients with refractory or recurrent AML, MDS, and JMML.

Start Date28 Mar 2025

Sponsor / Collaborator

The Children's Oncology Group Foundation, Inc.

[+2]

NCT05583552

/ Active, not recruitingPhase 2

A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients With HR Myelodysplastic Syndromes or AML Failing HMA-based Therapy

The purpose of this study is to evaluate the efficacy, in terms of hematologic improvement, and safety of imetelstat in participants with high-risk (HR) myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that is relapsed/refractory to hypomethylating agents (HMAs) treatment. Responding patients are eligible to continue treatment until loss of response/disease progression.

Start Date05 Jun 2023

Sponsor / Collaborator

GCP Service International Ltd & Co KG

[+5]

NCT05371964

/ RecruitingPhase 1

An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Patients With Myelofibrosis

The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the safety and clinical activity of the R2PD of imetelstat in combination with ruxolitinib in participants with MF in Part 2.

Start Date04 May 2022

Sponsor / Collaborator

Geron Corp.

100 Clinical Results associated with Geron Corp.

0 Patents (Medical) associated with Geron Corp.

416

Literatures (Medical) associated with Geron Corp.

05 Nov 2024·Blood

Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes

Author: Platzbecker, Uwe ; Zeidan, Amer M. ; Jonasova, Anna ; Komrokji, Rami S. ; Dougherty, Souria ; Navada, Shyamala ; Shah, Sheetal ; Xia, Qi ; Buckstein, Rena ; Savona, Michael R. ; Sekeres, Mikkael A. ; Mittelman, Moshe ; Madanat, Yazan F ; Germing, Ulrich ; Raza, Azra ; Sun, Libo ; Fenaux, Pierre ; Thépot, Sylvain ; Diez-Campelo, Maria ; Valcarcel, David ; Santini, Valeria

Introduction: Limited treatment options are available for patients with red blood cell (RBC) transfusion-dependent (TD) lower-risk myelodysplastic syndromes (LR-MDS). Imetelstat (IME), a first-in-class, direct, and competitive inhibitor of telomerase activity, was approved by the United States Food and Drug Administration in June 2024 for the treatment of RBC-TD LR-MDS in patients who were relapsed or refractory to or ineligible for erythropoiesis-stimulating agents (ESA) based on the results of the pivotal IMerge trial (NCT02598661). IMerge demonstrated significant and durable efficacy of IME (n=118) versus placebo (n=60) for ≥8-week, ≥24-week, and ≥1-year RBC-transfusion independence (TI), with a generally manageable safety profile in this patient population (Platzbecker U, Santini V, et al. Lancet. 2024). This analysis pooled data from the 3 parts of the IMerge trial (phase 2, phase 3 and QTc study) to investigate the effect of prior therapies on the clinical activity of IME.Methods: IMerge was a phase 2/3 trial with a clinical QTc study that enrolled patients with heavily RBC-TD LR-MDS who were ESA-ineligible or relapsed/ refractory. IME was administered intravenously every 4 weeks at 7.1 mg/kg (equivalent to 7.5 mg/kg IME sodium). Prior lenalidomide (LEN) and prior hypomethylating agent (HMA) use were exclusion criteria in phase 3 only. In this analysis, IME-treated patients (N=226) were pooled from phase 2, phase 3, and the QTc study of IMerge and analyzed on the basis of prior treatment as follows: ± ESA, luspatercept (LUSP), LEN, and HMA. Prior treatment was not exclusive; patients may have received >1 prior therapy. Outcomes included ≥8-week and ≥24-week RBC-TI, rates of hematologic improvement-erythroid (HI-E) based on the revised International Working Group (IWG) 2018 criteria, transfusion reduction of ≥4 U/8 weeks, and a hemoglobin (Hb) rise of ≥1.5 g/dL for ≥8 weeks.Results: As previously presented, data from the IMerge phase 3 pivotal analysis demonstrated that patients treated with IME (n=118) had ≥8-week and ≥24-week RBC-TI rates of 40% and 28%, respectively, 42% met HI-E (IWG 2018) criteria, 60% had transfusion reductions of ≥4 U/8 weeks, and 34% had a Hb rise of ≥1.5 g/dL for ≥8 weeks (Platzbecker U, Santini V, et al. Lancet. 2024). In the current analysis of all IME-treated patients pooled in IMerge (N=226), 204 had prior treatment with an ESA and 22 were ineligible for ESAs; 35 had prior LUSP, 26 had prior LEN, and 22 had prior HMA treatment. Of IME-treated patients with prior ESA therapy, 40% and 28% achieved ≥8-week and ≥24-week RBC-TI, respectively, 43% met HI-E, 64% had a transfusion reduction of ≥4 U/8 weeks, and 33% had a Hb rise of ≥1.5 g/dL for ≥8 weeks. In IME-treated patients ineligible for ESA therapy, 36% and 14% achieved ≥8-week and ≥24-week RBC-TI, respectively, 41% met HI-E, 64% had a transfusion reduction of ≥4 U/8 weeks, and 2% had a Hb rise of ≥1.5 g/dL for ≥8 weeks. Of IME-treated patients who had prior treatment with LUSP, 29% and 20% achieved ≥8-week and ≥24-week RBC-TI, respectively, 26% met HI-E, 69% had a transfusion reduction of ≥4 U/8 weeks, and 29% had a Hb rise ≥1.5 g/dL for ≥8 weeks. Of IME-treated patients with prior LEN treatment, 23% and 12% achieved ≥8-week and ≥24-week RBC-TI, respectively, 31% met HI-E, 54% had a transfusion reduction of ≥4 U/8 weeks, and 19% had a Hb rise of ≥1.5 g/dL for ≥8 weeks. Of the 22 IME-treated patients who had prior treatment with HMA, 14% and 9% achieved ≥8-week and ≥24-week RBC-TI, respectively, 18% met HI-E, 50% had a transfusion reduction of ≥4 U/8 weeks, and 14% had a Hb rise of ≥1.5 g/dL for ≥8 weeks.Conclusions: Patients who were ESA-ineligible or who had prior treatment with LUSP, LEN, or HMA in IMerge experienced clinical benefit from IME treatment, though the number of patients was small. Given the evolving therapeutic landscape for LR-MDS and the limited data available on outcomes in later lines of treatment, these results have important clinical implications, suggesting that IME demonstrates clinical activity regardless of prior therapies.

05 Nov 2024·Blood

PEPN2312: A Pediatric Early Phase Clinical Trials Network (PEP-CTN) Phase 1 Trial of Imetelstat with Fludarabine/Cytarabine in Pediatric Patients with Relapsed/Refractory AML, MDS, or JMML

Author: Stevens, Alexandra McLean ; Liu, Xiaowei ; Militano, Olga ; Weigel, Brenda J. ; Cooper, Todd M ; Fox, Elizabeth ; Reid, Joel M ; Navada, Shyamala ; Tasian, Sarah K. ; Minard, Charles G ; O'Brien, Maureen M.

Introduction:Survival of children with relapsed/refractory (r/r) acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and juvenile myelomonocytic leukemia (JMML) remains dismal, and successful treatment approaches are limited. Myeloid leukemias frequently have high telomerase expression, and neoplastic progenitor cells have relatively shorter telomeres compared to normal tissues due to the balance between frequent malignant cell division and compensatory increased telomerase activity. In one study, the 5-year overall survival (OS) in children with AML and lower telomerase activity was 88% compared to 43% for those with higher activity, suggesting potential prognostic and therapeutic importance of telomerase in this population (Verstovsek Cancer 2003).Imetelstat is a first-in-class telomerase inhibitor approved by the FDA in 2024 for the treatment of adult patients with low-to-intermediate-1 risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia who are r/r/ineligible for erythropoiesis-stimulating agents. . Imetelstat has also been shown to drive AML cells into ferroptosis (Bruedigam Nature Cancer 2024). The Children's Oncology Group (COG) previously conducted the ADVL1112 Phase 1 study of imetelstat monotherapy in children with r/r solid tumors or lymphomas (Thompson CCR 2013). Imetelstat was administered intravenously on Days 1 and 8 of a 21-day cycle. The recommended phase 2 dose (RP2D) was 268 mg/m2. Imetelstat was well-tolerated with no grade >3 non-hematologic toxicities and one dose-limiting thrombocytopenia observed in a subject treated at the RP2D. In preclinical studies, imetelstat was active against leukemia stem cells in pediatric AML patient derived xenograft models (Barwe J Clin Med, 2022).Methods:PEPN2312 is an open-label, multi-center phase 1 study of imetelstat in combination with fludarabine/high dose cytarabine (FLA) for patients with AML in second or greater relapse, refractory to re-induction after first relapse, or r/r MDS or JMML (NCT06247787). The primary objective of this study is to estimate the maximum tolerated dose (MTD) and/or RP2D of imetelstat in combination with FLA in this patient population. Secondary objectives include toxicity assessment, pharmacokinetics, clinical response/minimal residual disease assessments per standard criteria, and OS. Exploratory analyses will be conducted to analyze telomerase activity in peripheral blood mononuclear cells, conduct pharmacodynamic studies, and evaluate any changes in cytogenetic and mutational abnormalities. Eligible patients must be between the ages of 1 to 18 at the time of study enrollment with Lansky/Karnofsky performance status of ≥50. Patients with leukemia must have platelet count >25,000/µL and hemoglobin >8 g/dL (transfusions allowed). Patients known to have a congenital bone marrow failure syndrome are excluded.This study will use the Rolling 6 design to estimate the MTD/RP2D. The starting dose of imetelstat (DL1) is 212 mg/m2 IV over 2 hours (80% of the single-agent RP2D) given on days 1 and 8 of a 28-day cycle in combination with FLA administered days 2-6. Premedication for infusion reactions with an antihistamine and corticosteroid are required prior to each dose of imetelstat. Patients may receive up to 2 cycles of therapy in the absence of progressive disease or unacceptable toxicity as graded by CTCAE version 5.0. Response assessment will be performed via morphology and central flow cytometry analysis for patients with AML and standard response criteria for patients with JMML or MDS (Niemeyer Haematologica 2015; Zeidan Blood 2023). One dose escalation to 268 mg/m2 (DL2) will be explored if DL1 is deemed safe. Intra-patient dose escalation is not permitted. Pharmacokinetic sampling will be performed during cycle 1. Once the MTD/RP2D is determined, further assessment of safety and preliminary activity of imetelstat and FLA chemotherapy will occur in an expansion cohort of up to 6 additional patients treated at the MTD/RP2D. PEPN2312 was activated in July 2024 and will enroll at 21 participating COG/PEP-CTN sites.

05 Nov 2024·Blood

Correlation of Patient-Reported Outcomes with Red Blood Cell Transfusion Reduction and Rise in Hemoglobin in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Trial

Author: Regnault, Antoine ; Diez-Campelo, Maria ; Sekeres, Mikkael A. ; Zeidan, Amer M. ; Sun, Libo ; Creel, Kristin ; Shah, Sheetal ; Komrokji, Rami S. ; Fenaux, Pierre ; Sengupta, Nishan ; Savona, Michael R. ; Valcarcel, David ; Platzbecker, Uwe ; Dougherty, Souria ; Madanat, Yazan F. ; Navada, Shyamala ; Oliva, Esther Natalie ; Wan, Ying ; Santini, Valeria

Introduction: Quality of life (QOL) in patients with lower-risk myelodysplastic syndromes (LR-MDS) often declines as anemia and associated symptoms (such as fatigue) worsen, and progressive dependence on red blood cell (RBC) transfusions affects daily life. Imetelstat, a first-in-class, competitive inhibitor of telomerase activity, was recently approved by the United States Food and Drug Administration for patients with heavily RBC-transfusion dependent (TD) LR-MDS who are relapsed or refractory to or ineligible for erythropoiesis-stimulating agents (ESA), based on results of the randomized, double-blind, placebo-controlled, phase 3 IMerge trial (NCT02598661). As previously reported in IMerge, treatment with imetelstat resulted in clinically meaningful and statistically significant increases in ≥8-week and ≥24-week RBC transfusion independence (TI), with 50% of imetelstat-treated patients and 40% of placebo recipients who experienced a sustained, meaningful improvement in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue (Platzbecker U, Santini V, et al. Lancet. 2024). Here, we further explore treatment effects and improvement in patient-reported outcomes (PRO) across subgroups in IMerge.Methods: Adults with RBC-TD LR-MDS who were relapsed or refractory to or ineligible for ESAs and lenalidomide- and hypomethylating agent-naive were randomized to imetelstat (7.1 mg/kg active dose, equivalent to 7.5 mg/kg imetelstat sodium) or placebo administered as 2-hour intravenous infusions every 4 weeks. PROs were assessed with validated FACIT-Fatigue, Functional Assessment of Cancer Therapy-Anemia (FACT-An), and the Quality of Life in Myelodysplasia Scale (QUALMS) questionnaires. FACIT-Fatigue assessed fatigue for all patients and across subgroups (ring sideroblast-positive [RS+] vs RS-negative [RS−]; baseline transfusion burden [4-6 U/8weeks vs >6 U/8 weeks]). Sustained meaningful improvement in fatigue was defined as a ≥3-point increase in FACIT-Fatigue score for ≥2 consecutive assessments.Results: A total of 175 patients (118 imetelstat, 57 placebo) comprised the PRO population. In these post-hoc analyses in RS+ and RS− groups, respectively, sustained, meaningful improvement in fatigue was achieved by 55% and 43% of imetelstat-treated patients; differences (95% CI) versus placebo appeared to favor imetelstat (9% [−12, 29] for RS+ and 13% [−15, 36] for RS−). Similarly, in patients with prior transfusion burdens of 4-6 U/8 weeks or >6 U/8 weeks, respectively, sustained improvement in fatigue was achieved by 44% and 57% of imetelstat-treated patients; differences (95% CI) versus placebo appeared to favor imetelstat (8% [−15, 29] for 4-6 U/8 weeks and 11% [−13, 34] for >6 U/8 weeks). Similar to the RBC-TI response and improvement in fatigue association, for imetelstat-treated patients with versus in those without a ≥1.5-g/dL increase in hemoglobin (Hb) lasting ≥8 weeks, improvements in fatigue were seen in 70% (28/40) versus 40% of patients, respectively (31/78; P=.003); in those with versus in those without transfusion reduction of ≥4 U/8 weeks, improvements were seen in 69% (49/71) versus 21% of patients (10/47; P<.001). The QUALMS and FACT-An analyses suggested that imetelstat maintained QOL and anemia symptoms, while placebo recipients experienced worsening QOL and anemia symptoms. For imetelstat versus placebo, respectively, least squares mean changes from baseline to cycle 30 scores were as follows: QUALMS total (−0.55 vs −5.21; P=.016), QUALMS physical burden (−0.41 vs −6.75; P=.007), FACT-An total (−1.60 vs −9.72; P=.005), and FACT-An physical well-being (−0.43 vs −1.16; P=.197).Conclusions: Among imetelstat-treated patients enrolled in the IMerge trial, improvement in fatigue was associated with a rise in Hb and reductions in transfusion burden. In addition, more imetelstat-treated patients experienced maintenance of QOL and anemia symptoms compared with worsening with placebo. Imetelstat appears to offer the advantage of sustained RBC-TI while maintaining QOL in patients with RBC-TD LR-MDS.

152

News (Medical) associated with Geron Corp.

19 Dec 2024

·www.businesswire.com

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--( BUSINESS WIRE )--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 72,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on December 18, 2024, at an exercise price $3.77 per share, which is equal to the closing price of Geron common stock on the date of grant. The stock options have a 10-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment for the respective employees and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates. All of the stock options were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the stock option agreements covering the grants and Geron’s 2018 Inducement Award Plan, which was adopted December 14, 2018, and provides for the granting of stock options to new employees. About Geron Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO™ (imetelstat) is approved in the United States for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn .

Phase 3Drug Approval

18 Dec 2024

·www.businesswire.com

Headlamp Health Appoints Veteran Healthcare Technology Leader as Chief Executive Officer and Board Member

SAN FRANCISCO--( BUSINESS WIRE )--Headlamp Health, a digital health company on the forefront of precision psychiatry, today announced the appointment of Erwin Estigarribia as Chief Executive Officer to spearhead the next phase of growth and commercialization for the company. Estigarribia brings more than 25 years of expertise in global business transformation, fundraising, product development and commercialization, and strategic partnerships in the life sciences industry to his new role as CEO of Headlamp. “Throughout his distinguished career, Erwin has developed a proven track record of success with driving substantial growth and building high-performing teams,” said Tom Chavez, Chairman of the Board, Superset. “Headlamp has reached a pivotal moment to accelerate growth under the leadership of a seasoned expert who can foster innovation and help our amazing team scale and grow. We are excited to welcome Erwin to the team and are confident in his ability to help us realize the company vision.” Headlamp provides scalable, innovative solutions to address the challenges of the global mental health crisis. Each year, an estimated one in eight adults experiences a mental health condition 1 , yet millions go without the care they need. Clinicians are overwhelmed by soaring demand, placing immense pressure on an already fragile system. The ripple effects of mental health touch every corner of society and impact families, workplaces, and communities. Estigarribia joins Headlamp at a time of rapid growth in the mental health technology market, which is projected to reach $20 billion by 2030 2 . This surge reflects a growing awareness that traditional care systems alone cannot meet the rising demand for care. As Headlamp’s CEO, Estigarribia will focus on broadening access for clinicians, patients and researchers to empower them with a more comprehensive and higher-resolution view of mental health. “Headlamp is uniquely positioned to create a step change in care to improve the lives of the millions that are impacted by a mental health diagnosis,” said Estigarribia. “By removing inefficiencies in the psychiatry space, we can provide patients and clinicians with accurate and actionable data leveraging Artificial Intelligence to create patient-specific solutions. I am honored to have the opportunity to lead this company through its next phase of growth, as it aligns perfectly with my expertise and passion for bringing solutions to patients, clinicians, and researchers.” Prior to joining Headlamp, Estigarribia served as President and CEO of InterVenn Biosciences, the company responsible for launching the world’s first glycoproteomic-AI test. While serving as Chief Operating Officer at InterVenn, his leadership and vision earned him recognition as one of the Top 25 COOs in Healthcare in 2022 by The Healthcare Technology Report , highlighting his dedication to operational excellence and groundbreaking innovation. Estigarribia has held executive leadership positions at global companies such as Chiron, Novartis, Geron, Nugen, CardioDX, and Applied Proteomics. He achieved a Bachelor of Engineering in Chemical and Bioprocess Engineering with Honors and Distinction from Swinburne University of Technology in Australia. About Headlamp Health Headlamp Health is transforming mental health care with tools to help bring precision psychiatry into clinical practice. Clinicians gain a comprehensive, 360-degree view of their patients through access to their past medical history (sourced from over 70,000 hospitals, clinics, and pharmacies nationwide), behavioral tracking, passive wearable data, and psychological assessments. This holistic approach helps inform smarter treatment planning and more discrete progress monitoring. Through the Headlamp mobile app, patients can access their health history and track their progress over time and between appointments, to build greater awareness around their condition. For more information, visit headlamp.com . Headquartered in San Francisco, Headlamp is a Superset company. For more information on Superset, visit superset.com . Source: World Health Organization, Mental Health Disorders. https://www.who.int/news-room/fact-sheets/detail/mental-disorders Verified Market Research, Mental Health Technology Market Size And Forecast. https://www.verifiedmarketresearch.com/product/mental-health-technology-market/

Executive Change

13 Dec 2024

·endpts.com

EMA's committee says expanded label for Lilly's Mounjaro into sleep apnea not necessary

The European Medicines Agency’s human medicines committee (CHMP) handed down 17 recommendations for drug approvals on Friday but said a label expansion of Eli Lilly’s blockbuster diabetes drug Mounjaro into obstructive sleep apnea isn’t necessary. The CHMP wrote in its decision that “the use of Mounjaro in this group of people is already covered by the approved indication for weight management,” and that “a separate indication for the treatment of moderate to severe OSA in adults with obesity is not needed.” CHMP also said in a Q&A on the decision that it “acknowledged that Mounjaro improves obstructive sleep apnea in adults with obesity.” The drug, known generically as tirzepatide, is marketed as Zepbound for obesity and Mounjaro for type 2 diabetes. Lilly has already filed for a label expansion with the FDA. The 17 new CHMP recommendations for drugs includes Gilead’s seladelpar for the autoimmune liver disease primary biliary cholangitis, and Merck’s Welireg for von Hippel-Lindau disease tumors and advanced clear cell renal cell carcinoma. Welireg is the first medicine developed to treat the rare, genetic von Hippel-Lindau disease, which can lead to tumors growing in different parts of the body. The committee also recommended BridgeBio’s Beyonttra for the wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy. Six biosimilars and eight other drugs saw label extensions, including: Geron’s Rytelo also won a CHMP nod for adults with transfusion-dependent anemia caused by myelodysplastic syndromes. Leerink analysts wrote in a Friday note that “in the coming months” they expect to learn more about Geron’s EU plans, but progress on a 2025 US launch “is what matters for the stock.”

Drug Approval

100 Deals associated with Geron Corp.

100 Translational Medicine associated with Geron Corp.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 07 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Imetelstat ( Telomerase )	myelodysplastic anemia More	Approved
VAC-1(Wuchan Zhongda Geron) ( LAMP-1 x TERT )	Acute Myeloid Leukemia More	Phase 2
GRNCHND-1	Cartilage Diseases More	Discontinued
TAT-2 ( Telomerase )	HIV Infections More	Discontinued
GRNIC-1	Diabetes Mellitus, Type 1 More	Discontinued

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis